Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rechallenge with Dabrafenib and Trametinib in BRAF-positive Anaplastic Thyroid Cancer
NCT06362694Phase 2Recruiting
- Sponsor
- Saint Petersburg State University
- Start
- Mar 2024
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dabrafenib + trametinib and trametinib in anaplastic thyroid cancer (ATC), sponsored by Saint Petersburg State University. Primary endpoints: Objective Response Rate, Progression-Free Survival at 2 years and 1 more. Started Mar 2024; status: recruiting.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
anaplastic thyroid cancer (ATC)
Beyond the preview
Go deeper on NCT06362694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06362694.